These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

690 related articles for article (PubMed ID: 3130683)

  • 21. Trypanocidal activity of 4 isopropyl salicylaldehyde and 4-isopropyl salicylic acid on Trypanosoma cruzi.
    Nogueda-Torres B; Rodríguez-Paez L; Ramírez IB; Ramírez CW
    Rev Latinoam Microbiol; 2001; 43(1):1-6. PubMed ID: 17061565
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A rapid method for testing in vivo the susceptibility of different strains of Trypanosoma cruzi to active chemotherapeutic agents.
    Filardi LS; Brener Z
    Mem Inst Oswaldo Cruz; 1984; 79(2):221-5. PubMed ID: 6443014
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nifurtimox chemotherapy: collateral effects in treated Trypanosoma cruzi infected patients.
    Murcia L; Carrilero B; Albajar Viñas P; Segovia M
    Rev Esp Quimioter; 2012 Mar; 25(1):74-5. PubMed ID: 22488545
    [No Abstract]   [Full Text] [Related]  

  • 24. A flow cytometer-based method to simultaneously assess activity and selectivity of compounds against the intracellular forms of Trypanosoma cruzi.
    Miranda CG; Solana ME; Curto MLA; Lammel EM; Schijman AG; Alba Soto CD
    Acta Trop; 2015 Dec; 152():8-16. PubMed ID: 26272680
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Variation in susceptibility to benznidazole in isolates derived from Trypanosoma cruzi parental strains.
    Veloso VM; Carneiro CM; Toledo MJ; Lana M; Chiari E; Tafuri WL; Bahia MT
    Mem Inst Oswaldo Cruz; 2001 Oct; 96(7):1005-11. PubMed ID: 11685270
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Time and dose-dependence evaluation of nitroheterocyclic drugs for improving efficacy following Trypanosoma cruzi infection: A pre-clinical study.
    Mazzeti AL; Diniz LF; Gonçalves KR; Nascimento AFS; Spósito PAF; Mosqueira VCF; Machado-Coelho GLL; Ribeiro I; Bahia MT
    Biochem Pharmacol; 2018 Feb; 148():213-221. PubMed ID: 29309767
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An update on benznidazole for the treatment of patients with Chagas disease.
    Thakare R; Dasgupta A; Chopra S
    Drugs Today (Barc); 2018 Jan; 54(1):15-23. PubMed ID: 29569658
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chemotherapy of Chagas' disease: status and new developments.
    Cerecetto H; González M
    Curr Top Med Chem; 2002 Nov; 2(11):1187-213. PubMed ID: 12171581
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Activities of the triazole derivative SCH 56592 (posaconazole) against drug-resistant strains of the protozoan parasite Trypanosoma (Schizotrypanum) cruzi in immunocompetent and immunosuppressed murine hosts.
    Molina J; Martins-Filho O; Brener Z; Romanha AJ; Loebenberg D; Urbina JA
    Antimicrob Agents Chemother; 2000 Jan; 44(1):150-5. PubMed ID: 10602737
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of nucleic acid amplification assays in monitoring treatment response in chagas disease: Usefulness in clinical trials.
    Sulleiro E; Muñoz-Calderon A; Schijman AG
    Acta Trop; 2019 Nov; 199():105120. PubMed ID: 31376368
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Evaluation of complement mediated lysis technic in patients with chronic Chagas' disease treated with trypanocidal drugs].
    Levy AM; Pereira VL; Boainain E
    Rev Inst Med Trop Sao Paulo; 1988; 30(1):32-9. PubMed ID: 3146793
    [No Abstract]   [Full Text] [Related]  

  • 32. Microsatellite and mini-exon analysis of Mexican human DTU I Trypanosoma cruzi strains and their susceptibility to nifurtimox and benznidazole.
    Martínez I; Nogueda B; Martínez-Hernández F; Espinoza B
    Vector Borne Zoonotic Dis; 2013 Mar; 13(3):181-7. PubMed ID: 23421890
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Therapy of the chronic phase of the experimental infection by Trypanosoma cruzi with benzonidazole and nifurtimox].
    Andrade SG; Magalhães JB; Pontes AL
    Rev Soc Bras Med Trop; 1989; 22(3):113-8. PubMed ID: 2518608
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Trypanocidal effect of the benzyl ester of N-propyl oxamate: a bi-potential prodrug for the treatment of experimental Chagas disease.
    Wong-Baeza C; Nogueda-Torres B; Serna M; Meza-Toledo S; Baeza I; Wong C
    BMC Pharmacol Toxicol; 2015 Apr; 16():10. PubMed ID: 25896924
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The challenge of Chagas' disease chemotherapy: an update of drugs assayed against Trypanosoma cruzi.
    de Castro SL
    Acta Trop; 1993 Apr; 53(2):83-98. PubMed ID: 8098901
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Perspectives in Chagas disease treatment.
    Oliveira GB; Avezum Á; Cordeiro Mattos AJ
    Glob Heart; 2015 Sep; 10(3):189-92. PubMed ID: 26407515
    [No Abstract]   [Full Text] [Related]  

  • 37. Recent clinical trials for the etiological treatment of chronic chagas disease: advances, challenges and perspectives.
    Urbina JA
    J Eukaryot Microbiol; 2015; 62(1):149-56. PubMed ID: 25284065
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Persistent infections in chronic Chagas' disease patients treated with anti-Trypanosoma cruzi nitroderivatives.
    Braga MS; Lauria-Pires L; Argañaraz ER; Nascimento RJ; Teixeira AR
    Rev Inst Med Trop Sao Paulo; 2000; 42(3):157-61. PubMed ID: 10887376
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activity of the new triazole derivative albaconazole against Trypanosoma (Schizotrypanum) cruzi in dog hosts.
    Guedes PM; Urbina JA; de Lana M; Afonso LC; Veloso VM; Tafuri WL; Machado-Coelho GL; Chiari E; Bahia MT
    Antimicrob Agents Chemother; 2004 Nov; 48(11):4286-92. PubMed ID: 15504854
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enantiomers of nifurtimox do not exhibit stereoselective anti-Trypanosoma cruzi activity, toxicity, or pharmacokinetic properties.
    Moraes CB; White KL; Braillard S; Perez C; Goo J; Gaspar L; Shackleford DM; Cordeiro-da-Silva A; Thompson RC; Freitas-Junior L; Charman SA; Chatelain E
    Antimicrob Agents Chemother; 2015; 59(6):3645-7. PubMed ID: 25845874
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.